Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019682 · ClinicalTrials.gov registry record · Phase 3
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 185
- Enrollment target
NCT00019682: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00019682 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 185 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00019682, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 185 participants
- Enrollment target
Study Summary
This randomized phase III trial studies aldesleukin with vaccine therapy to see how well it works compared to aldesleukin alone in treating patients with melanoma that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. Aldesleukin may stimulate a person's white blood cells to kill melanoma cells. Vaccines may make the body build an immune response to kill tumor cells. It is not yet known whether combining aldesleukin with vaccine therapy is more effective than aldesleukin alone in treating melanoma.
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- BIOLOGICAL Aldesleukin
- DRUG Montanide ISA 51 VG
- BIOLOGICAL gp100 Antigen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 1999-12 |
| Est. Completion | 2011-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00019682
The ClinicalTrials.gov registry entry for NCT00019682 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.
NCT00019682 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00019682 about?
NCT00019682 is a clinical study titled "Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma". This randomized phase III trial studies aldesleukin with vaccine therapy to see how well it works compared to aldesleukin alone in treating patients with melanoma that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. Aldesleukin may stimulate a person'...
What is the current status of trial NCT00019682?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 185 participants. The study started on 1999-12. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00019682?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Aldesleukin (BIOLOGICAL), Montanide ISA 51 VG (DRUG), gp100 Antigen (BIOLOGICAL).
Who is sponsoring clinical trial NCT00019682?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.